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Abstract
Introduction: Smoking has been causally linked to 12 tobacco-related cancers: oral cavity and 
pharynx, esophagus, stomach, colon and rectum, liver, pancreas, larynx, lung, cervix, bladder, 
kidney, and acute myeloid leukemia. Tobacco-related cancers–related morbidity and mortality 
have been well described, but little is known about the prevalence of tobacco-related cancer 
hospitalizations and associated costs. This study estimates the annual number of tobacco-related 
cancer hospitalizations and their associated direct medical costs in the U.S.
Methods: This study examined data from the 2014 National Inpatient Sample, the largest 
publicly available all-payer inpatient care database in the U.S. The authors calculated number of 
hospitalizations, total costs, length of stay, and cost per stay for tobacco-related cancer 
hospitalizations and cancer hospitalizations not related to tobacco.
Results: In 2014, there were an estimated 461,295 annual tobacco-related cancer hospitalizations 
at a cost of $8.2 billion in the U.S. Tobacco-related cancers accounted for 45% of total cancer 
hospitalizations and cancer hospitalization costs. Compared with cancer hospitalizations not 
related to tobacco, tobacco-related cancer hospitalizations had a longer mean length of stay (6.8 vs 
5.7 days).
Conclusions: The burden of tobacco-related cancer hospitalizations is substantial in the U.S. 
These findings highlight the importance of tobacco prevention and cessation efforts to decrease the 
burden of tobacco-related cancers in the U.S.
INTRODUCTION
Tobacco use is the leading preventable cause of disease and premature death in the U.S., 
causing more than 480,000 deaths annually.1 Since the U.S. Surgeon General first linked 
smoking to cancer in 1964, cigarette smoking has been causally linked to 12 cancers: oral 
cavity and pharynx; esophagus; stomach; colon and rectum; liver; pancreas; larynx; lung, 
bronchus, and trachea (lung); uterine cervix (cervix); urinary bladder (bladder); kidney and 
renal pelvis (kidney); and acute myeloid leukemia.1 Together, these 12 cancers are defined 
as tobacco-related cancers (TRCs).1 Since 1964, more than 6.5 million Americans have died 
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as a result of TRCs. Cigarette smoking accounts for approximately 30% of all cancer deaths 
in the U.S., including nearly 90% of lung cancer deaths.1–5 Although the risks of developing 
cancer among people who use tobacco are well documented, less is known about the 
prevalence and cost of TRC hospitalizations.6–9 This study estimates the annual number of 
TRC hospitalizations and their associated direct medical costs in the U.S.
METHODS
The authors analyzed the 2014 Healthcare Cost and Utilization Project’s National Inpatient 
Sample (NIS), the largest publicly available all-payer inpatient care database in the U.S.10 
TRCs were defined as those cancers that the U.S. Surgeon General has causally linked to 
smoking.1 Because tobacco use is one of many factors that increases the risk of TRCs, 
tobacco use may not have contributed to each TRC hospitalization, and the estimated 
number of TRC cases attributable to smoking varies by cancer type.11 TRC cancer 
hospitalizations among adults aged ≥18 years were identified using the first-listed (primary) 
diagnosis code from the ICD-9-CM.12 The following ICD-9 codes were used: oral cavity 
and pharynx (140.0–149.9); esophagus (150.0–150.9); stomach (151.0–151.9); colon and 
rectum (153.0–153.9, 154.0–154.8); liver (155.0–155.2); pancreas (157.0–157.9); larynx 
(161.0–161.9); lung, bronchus, and trachea (162.0–162.9); cervix (180.0–180.9); bladder 
(188.0–188.9); kidney and renal pelvis (189.0–189.1); and acute myeloid leukemia (205.00–
205.02). Because lung cancer comprises the largest group of TRCs, separate analyses for 
hospitalizations related to lung cancer were conducted.
Patient, payer, and hospital characteristics were examined for each visit. Generalized linear 
models with a gamma distribution and a log link were used to estimate length of stay and 
cost per stay. All regressions controlled for age, sex, race/ethnicity, insurance status, number 
of chronic conditions, and admission through the emergency department. Adjusted estimates 
are presented as predictive margins. The predicted margins method directly standardizes the 
outcome of each group to the covariate distribution of the overall population.13 The authors 
estimated the mean length of stay, mean cost per stay, mean cost per day, and total annual 
costs. The NIS includes hospital charges rather than costs; however, cost-to-charge ratios 
were used, an accepted method for estimating costs from charges.14 The NIS excludes 
physician and professional fees, and does not capture TRCs treated in other healthcare 
settings. Data were weighted to provide nationally representative estimates and analyzed 
with Stata, version 14.2. The analysis was conducted in September 2017.
RESULTS
In 2014, there were an estimated 461,295 hospitalizations with a TRC identified as the 
principal diagnosis (Table 1). Of these hospitalizations, the most common cancer type was 
colorectal (28%), followed by lung (27%), kidney (10%), pancreas (8%), bladder (6%), liver 
(5%), and stomach (5%). There were an estimated 573,550 cancer hospitalizations not 
related to tobacco. Compared with individuals hospitalized for cancers not related to 
tobacco, individuals hospitalized for TRCs were older, had lower household income, more 
chronic conditions, experienced higher in-hospital mortality rate, and a higher proportion 
were hospitalized in the South and Midwest.
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In 2014, the total cost of TRC hospitalizations was $8.2 billion (Table 2). Of this, 23% was 
due to lung cancer ($1.8 billion). The total annual cost of cancer hospitalizations not related 
to tobacco was $10.1 billion. Compared with cancer hospitalizations not related to tobacco, 
TRC hospitalizations had a longer mean length of stay (6.8 vs 5.7 days).
DISCUSSION
This report presents national estimates of direct medical costs of TRC hospitalizations using 
the largest all-payer inpatient care database in the U.S. The study found 461,295 TRC 
annual hospitalizations in the U.S. with an estimated cost of $8.1 billion. TRCs accounted 
for 45% of total cancer hospitalizations and hospitalization costs in the U.S. in 2014.
TRC hospitalizations account for a significant proportion of smoking-related costs. 
Smoking-attributable healthcare spending is estimated to account for 6%–14% of total 
annual healthcare expenditures in the U.S.15–17 Annual smoking-related direct medical care 
costs in the U.S. have been estimated at $132 billion to $175 billion.3,16–19 These estimates 
suggest that TRC hospitalizations account for a significant portion of smoking-related direct 
medical care costs in the U.S. The current results indicate that the higher cost of TRC 
hospitalizations is primarily because of longer hospital stays. Although comorbid conditions 
were not included in this analysis, they may be a significant contributor to longer length of 
stays and associated costs.
Even though this study reports the cost of TRC hospitalizations, it also highlights 
opportunities to reduce TRC-related burden and cost through prevention programs. From 
2005 to 2015, smoking among adults in the U.S. decreased from 21% to 15%.20 Despite this 
decrease, smoking still accounts for approximately 30% of all cancer deaths in the U.S., 
including nearly 90% of lung cancer deaths.1–4 The National Academy of Medicine 
recommends implementing strategies shown to decrease cigarette sales and smoking 
prevalence.1,2 As the preventive impact of smoking cessation varies by age, smoking 
prevention may have greater long-term results when initiated at earlier ages.21,22 Supporting 
tobacco quitline interventions and comprehensive statewide tobacco control and cancer 
programs would also be beneficial.1,23–25 Support for programs such as the Centers for 
Disease Control and Prevention’s TIPS Campaign, which has demonstrated the effectiveness 
of media campaigns in increasing quit attempts, may also contribute to decreasing smoking 
prevalence.26 Increasing the availability of inpatient tobacco cessation services, which result 
in higher rates of smoking cessation and are cost effective, may lead to further decreases in 
smoking.27–29 These efforts may be particularly effective in states in the South and Midwest, 
which have the most TRC hospitalizations, highest smoking prevalence, and highest lung 
cancer rates in the U.S.25 Despite serious health risks, cigarette smoking prevalence is higher 
among cancer survivors compared with people without a history of cancer.29,30 Although 
tobacco cessation can improve prognosis and survival, evidence-based smoking cessation 
services are not available in many oncology settings.29
Limitations
This study has several limitations. These estimates may differ from a complete accounting of 
costs. Individual tobacco use information was not available in this dataset. Because smoking 
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is one of many factors that increase cancer risk, tobacco use may not have contributed to 
each TRC hospitalization. This may have resulted in some overestimation, especially for 
TRCs that have stronger associations with risk factors other than tobacco. The NIS contains 
discharge-level records but not patient-level records. Thus, individual patients discharged 
multiple times in one year are not able to be identified. Although including hospitalizations 
not caused by tobacco may have caused an overestimation of costs, excluding physician and 
professional services, and other treatments may have led to underestimation of total costs.
CONCLUSIONS
In summary, the authors estimate that the $8.1 billion annual cost of TRC hospitalizations 
accounts for 45% of all cancer hospitalization costs. National estimates of TRC 
hospitalization costs have the potential to inform program and policy development for cancer 
prevention, treatment, surveillance, and end-of-life care.31 This report highlights the 
importance of tobacco prevention and cessation efforts to reduce the cost and burden of TRC 
hospitalizations.
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Table 1
Characteristics of TRCa Hospitalizations Compared to Other Cancer-related Hospitalizations Among Adults 
(Aged ≥18 Years), NIS, 2014
Characteristics TRC hospitalizations
Hospitalizations related 
to lung cancer
TRC hospitalizations 
excluding lung cancer
Cancer hospitalizations 
not related to tobacco
n, unweighted (weighted)b 92,259 (461,295) 25,126 (125,630) 67,133 (335,665) 114,710 (573,550)
Patient characteristics
 Age
  18–44 years 5.6 (5.3, 5.8) 1.6 (1.4, 1.8) 7.0 (6.8, 7.3) 10.8 (10.4, 11.2)
  45–64 years 37.4 (36.8, 37.9) 33.8 (33.1, 34.6) 38.7 (38.1, 39.3) 43.7 (43.2, 44.1)
  ≥65 years 57.1 (56.4, 57.7) 64.6 (63.8, 65.3) 54.3 (53.6, 55.0) 45.5 (44.8, 46.3)
 Sex
  Male 55.4 (55.0, 55.7) 50.7 (50.1, 51.4) 57.1 (56.7, 57.5) 46.3 (45.6, 47.1)
  Female 44.6 (44.2, 45.0) 49.3 (48.6, 49.9) 42.9 (42.5, 43.3) 53.7 (52.9, 54.4)
 Race/ethnicity
  Non-Hispanic white 69.6 (68.1, 71.0) 74.1 (72.6, 75.5) 67.9 (66.4, 69.4) 67.6 (65.9, 69.3)
  Non-Hispanic black 11.6 (10.9, 12.2) 11.7 (11.0, 12.5) 11.5 (10.9, 12.2) 12.0 (11.3, 12.7)
  Asian or Pacific Islander 3.2 (2.8, 3.6) 2.6 (2.3, 2.9) 3.4 (3.1, 3.8) 3.1 (2.8, 3.5)
  Hispanic 7.6 (7.0, 8.3) 4.4 (3.9, 5.0) 8.8 (8.1, 9.6) 8.4 (7.7, 9.2)
  Other 2.9 (2.6, 3.3) 2.4 (2.1, 2.8) 3.1 (4.0, 6.7) 3.2 (2.8, 3.7)
 Household income
  Lowest quartile 26.6 (25.6, 27.7) 27.9 (26.7, 29.2) 26.2 (25.2, 27.2) 23.3 (22.3, 24.4)
  All other quartiles 71.2 (70.2, 72.2) 70.0 (68.8, 71.2) 71.6 (70.6, 72.7) 74.4 (73.4, 75.4)
 No. of chronic conditions
  0–1 11.5 (11.2, 11.8) 6.1 (5.7, 6.4) 13.5 (13.1, 13.9) 17.1 (16.6, 17.6)
  2–3 22.3 (21.9, 22.7) 18.5 (18.0, 19.1) 23.7 (23.3, 24.1) 26.1 (25.7, 26.5)
  4–5 25.2 (24.8, 25.5) 25.7 (25.1, 26.3) 24.9 (24.6, 25.3) 24.5 (24.1, 24.8)
  ≥6 41.1 (40.4, 41.7) 49.7 (48.8, 50.5) 37.8 (37.2, 38.5) 32.3 (31.7, 32.9)
 Received ED services
  Yes 34.8 (33.7, 35.9) 43.5 (42.3, 44.8) 31.5 (30.5, 32.6) 33.9 (32.7, 35.2)
 Patient disposition
  Routine 55.8 (55.0, 56.5) 50.6 (49.6, 51.7) 57.7 (56.9, 58.5) 61.0 (60.1, 61.8)
  Transfer 15.3 (14.9, 15.8) 15.8 (15.2, 16.4) 15.2 (14.7, 15.6) 15.4 (14.9, 15.9)
  Home health care 22.5 (21.9, 23.1) 24.0 (23.1, 24.8) 21.9 (21.2, 22.6) 18.9 (18.2, 19.6)
  Died in hospital 5.8 (5.6, 6.1) 9.0 (8.5, 9.4) 4.7 (4.5, 4.9) 4.4 (4.2, 4.6)
  Other 0.5 (0.4, 0.6) 0.6 (0.5, 0.8) 0.4 (0.4, 0.5) 0.4 (0.3, 0.4)
Payer information
 Expected primary payer
  Medicare 54.7 (54.0, 55.3) 61.8 (61.0, 62.6) 52.0 (51.3, 52.7) 44.8 (44.0, 45.5)
  Medicaid 10.4 (9.9, 11.0) 9.5 (9.0, 10.0) 10.8 (10.2, 11.4) 10.6 (10.0, 11.3)
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Characteristics TRC hospitalizations
Hospitalizations related 
to lung cancer
TRC hospitalizations 
excluding lung cancer
Cancer hospitalizations 
not related to tobacco
  Private 29.1 (28.3, 29.9) 23.2 (22.4, 24.1) 31.2 (30.4, 32.1) 38.9 (37.9, 40.0)
  Self-pay 2.7 (2.4, 2.9) 2.4 (2.2, 2.7) 2.8 (2.5, 3.1) 2.5 (2.2, 2.7)
  Other 3.0 (2.7, 3.2) 2.9 (2.6, 3.2) 3.0 (2.8, 3.3) 2.9 (2.7, 3.2)
Hospital characteristics
 Region
  Northeast 20.6 (19.0, 22.4) 20.7 (19.1, 22.4) 20.6 (18.9, 22.4) 22.1 (19.7, 24.7)
  Midwest 22.5 (20.9, 24.0) 23.6 (22.2, 25.1) 22.0 (20.3, 23.7) 21.8 (19.7, 24.1)
  South 39.1 (37.3, 40.9) 41.0 (39.3, 42.7) 38.3 (36.4, 40.3) 36.1 (33.6, 38.8)
  West 17.9 (16.8, 19.1) 14.7 (13.7, 15.7) 19.1 (17.8, 20.5) 19.9 (18.2, 21.8)
 Location/teaching status
  Rural 6.4 (5.9, 7.0) 7.0 (6.2, 7.9) 6.2 (5.7, 6.8) 4.2 (3.7, 4.7)
  Urban non-teaching 21.3 (20.3, 22.4) 23.6 (22.4, 24.8) 20.5 (19.5, 21.6) 17.1 (15.9, 18.2)
  Urban teaching 72.2 (71.0, 73.4) 69.4 (68.0, 70.8) 73.3 (72.0, 74.5) 78.8 (77.4, 80.1)
Note: Values are % (95% CI) unless otherwise noted.
a
TRC sites include oral cavity and pharynx; esophagus; stomach; colon and rectum; liver; pancreas; larynx; lung, bronchus, and trachea; uterine 
cervix; urinary bladder; kidney and renal pelvis; and acute myeloid leukemia.
bWeighted averages may not add up to total.
ED, emergency department; NIS, National Inpatient Sample; No., number; TRC, tobacco-related cancer.
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Table 2
Average Annual Cost and Length of Hospital Stays for TRCs, NIS 2014
Hospitalizations n
Length of stay, 
days (95% CI) Cost per stay, $ (95% CI)
Cost per day, $ (95% 
CI)
Total cost, $ (95% 
CI)
TRC hospitalizations 461,295 6.8 (6.7, 6.9) 17,677 (17,194, 18,160) 2,604 (2,569, 2,638) 8.15 (7.93, 8.38)
Hospitalizations related to 
lung cancer
125,630 5.7 (5.7, 5.8) 14,632 (14,306, 14,957) 2,548 (2,532, 2,564) 1.84 (1.80, 1.88)
TRC hospitalizations 
excluding lung cancer
335,665 7.2 (7.1, 7.3) 18,804 (18,230, 19,379) 2,622 (2,584, 2,660) 6.31 (6.12, 6.50)
Cancer hospitalizations not 
related to tobacco
573,550 5.7 (5.6, 5.8) 17,617 (16,978, 18,256) 3,068 (3,014, 3,121) 10.10 (9.74, 10.47)
Note: Weighted averages may not add up to total. Adjusted for age, sex, race/ethnicity, insurance status, number of chronic diseases, and admission 
through the emergency department. All costs are in 2014 dollars.
NIS, National Inpatient Sample; TRC, tobacco-related cancer.
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